IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 12, 2021 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that long-term follow up data from MINDACT, the prospective, randomized trial designed to further confirm the clinical utility of MammaPrint risk scoring when determining a breast cancer patient’s need for chemotherapy, was published in The Lancet Oncology, and can be viewed online here. As previously reported at the ASCO conference in May 2020, the European Breast Cancer Conference in October 2020, and highlighted in an oral presentation at SABCS in December 2020, the data published in The Lancet Oncology confirm MINDACT as a positive de-escalation study, and show that nearly half of women who would have Read More
Results support use of Agendia’s genomic tests to better tailor pre-operative treatment and timing for surgery IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from the prospective Neoadjuvant Breast Symphony Trial (NBRST) which demonstrate the predictive and prognostic abilities of MammaPrint® and BluePrint®, and underpin both assays’ pre-operative utility in pre-and post-menopausal patients. A poster highlighting these findings will be presented at the 38th Annual Miami Breast Cancer Conference. The poster, entitled Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients, outlines the first age-based analyses of MammaPrint and BluePrint assays in the pre-operative setting. As expected, the data show that pCR rates varied according to Read More
Agendia to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Thursday, February 04, 2021 02:00:00 PM (GMT) Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which runs February 17-19, 2021. Agendia Chief Executive Officer Mark Straley will participate in a fireside chat discussion on Thursday, February 18 at 11:00 AM EST. A link to the live webcast of Mr. Straley’s presentation will be available by visiting the News & Updates section of Agendia’s website at https://agendia.com/news/. A replay of the webcast will be available on the Agendia website for 90 days following the conclusion of the Read More
IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, which will take place from Monday, January 11 through Thursday, January 14, 2021. Agendia Chief Executive Mark Straley will give a virtual presentation on Thursday, January 14 at 2:35 PM EST. To access the audio stream of the virtual sessions click here. A link to the live audio webcast of Mr. Straley’s presentation will be available by visiting the News & Updates section of Agendia’s website at https://agendia.com/news/. A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast. About Agendia Agendia is a precision oncology company headquartered Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 11, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted in an oral presentation by Laura van’t Veer, Ph.D., Co-founder and Chief Research Officer, at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). These data highlight the ability of MammaPrint®, Agendia’s 70-gene breast cancer recurrence assay, to further stratify patients with clinically low risk breast cancer which could impact physician-patient discussions and treatment planning. MINDACT (Microarray In Node-Negative and 1-3 node-positive Disease may Avoid ChemoTherapy), the Phase 3, prospective, randomized clinical trial supported by the European Organization for Research and Treatment of Cancer (EORTC), Read More
Clinical utility of molecular subtyping and risk of recurrence profiling highlighted in largest-ever data set evaluating genomic testing in neoadjuvant setting First look at full 5-year NBRST trial outcome and survival data illustrate genomic diversity within all clinical subtypes of breast cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 10, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced new 5-year data from the NBRST trial that will be presented in a poster spotlight discussion Thursday, December 10, 2020 from 3:30pm-4:45pm CST at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). The poster, entitled 5-year outcomes in the NBRST trial: Preoperative MammaPrint® and BluePrint® breast cancer subtype is associated with neoadjuvant treatment response Read More
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.